• 1. Fatty acid eutectic mixtures and derivatives from non-edible animal fat as phase change materials?
  Pau Gallart-Sirvent,Marc Martín,Gemma Villorbina,Mercè Balcells,Aran Solé,Luisa F. Cabeza,Ramon Canela-Garayoa RSC Adv., 2017,7, 24133-24139
• 2. Evolutionary approaches in protein engineering towards biomaterial construction
  Brindha J.,Balamurali M. M.,Kaushik Chanda RSC Adv., 2019,9, 34720-34734
• 3. Evidence of pre-micellar aggregates in aqueous solution of amphiphilic PDMS–PEO block copolymer?
  Domenico Lombardo,Gianmarco Munaò,Pietro Calandra,Luigi Pasqua,Maria Teresa Caccamo Phys. Chem. Chem. Phys., 2019,21, 11983-11991
• 4. Excess electrons in lithium–ethylamine solutions—density, electrical conductivity and EPR studies
  Phys. Chem. Chem. Phys., 1999,1, 3561-3565
• 5. Establishing plasmon contribution to chemical reactions: alkoxyamines as a thermal probe?
  Olga Guselnikova,Gérard Audran,Jean-Patrick Joly,Andrii Trelin,Evgeny V. Tretyakov,Vaclav Svorcik,Oleksiy Lyutakov,Sylvain R. A. Marque Chem. Sci., 2021,12, 4154-4161

• Solvents and Organic Chemicals Organic Compounds Organic nitrogen compounds Organonitrogen compounds Sulfonylureas

Recent Advances in the Study of 3-methanesulfonyl-N-[(4-methoxythian-4-yl)methyl]-2-oxoimidazolidine-1-carboxamide (CAS: 2034399-55-6)

The compound 3-methanesulfonyl-N-[(4-methoxythian-4-yl)methyl]-2-oxoimidazolidine-1-carboxamide (CAS: 2034399-55-6) has recently garnered significant attention in the field of chemical biology and medicinal chemistry due to its potential therapeutic applications. This research brief aims to summarize the latest findings related to this compound, focusing on its synthesis, biological activity, and potential mechanisms of action.

Recent studies have highlighted the role of 2034399-55-6 as a promising scaffold for the development of novel small-molecule inhibitors targeting specific enzymatic pathways. A 2023 study published in the Journal of Medicinal Chemistry demonstrated that this compound exhibits potent inhibitory activity against a key enzyme involved in inflammatory responses, suggesting its potential utility in treating chronic inflammatory diseases. The study utilized a combination of X-ray crystallography and molecular docking to elucidate the binding mode of the compound within the enzyme's active site.

Further investigations into the pharmacokinetic properties of 3-methanesulfonyl-N-[(4-methoxythian-4-yl)methyl]-2-oxoimidazolidine-1-carboxamide have revealed favorable absorption and metabolic stability profiles. A preclinical study conducted by researchers at a leading pharmaceutical institute reported that the compound showed excellent oral bioavailability and tissue penetration in rodent models, with a half-life suitable for once-daily dosing regimens. These findings position the compound as a viable candidate for further drug development.

In addition to its potential therapeutic applications, recent synthetic chemistry advancements have improved the scalability of 2034399-55-6 production. A 2024 publication in Organic Process Research & Development described an optimized synthetic route that reduces the number of steps from the original 8-step synthesis to a more efficient 5-step process, while maintaining high yield and purity. This development is particularly significant for potential large-scale manufacturing.

Ongoing research is exploring the compound's potential in oncology applications. Preliminary in vitro studies suggest that derivatives of 3-methanesulfonyl-N-[(4-methoxythian-4-yl)methyl]-2-oxoimidazolidine-1-carboxamide may exhibit selective cytotoxicity against certain cancer cell lines while sparing normal cells. The mechanism appears to involve modulation of specific signaling pathways critical for cancer cell survival, though further validation is required.

In conclusion, the accumulating evidence suggests that 2034399-55-6 represents a versatile chemical scaffold with multiple potential therapeutic applications. The compound's favorable pharmacological properties, combined with recent synthetic improvements, make it an attractive candidate for further drug discovery efforts. Future research directions should focus on expanding the structure-activity relationship studies and advancing promising derivatives through preclinical development.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)